257 related articles for article (PubMed ID: 26495067)
1. Drug therapy of overactive bladder--what is coming next?
Andersson KE
Korean J Urol; 2015 Oct; 56(10):673-9. PubMed ID: 26495067
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for overactive bladder.
Karmarkar R; Khullar V
Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
[TBL] [Abstract][Full Text] [Related]
3. Potential Future Pharmacological Treatment of Bladder Dysfunction.
Andersson KE
Basic Clin Pharmacol Toxicol; 2016 Oct; 119 Suppl 3():75-85. PubMed ID: 26990140
[TBL] [Abstract][Full Text] [Related]
4. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Yamaguchi O
Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
[TBL] [Abstract][Full Text] [Related]
5. β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview.
Kaya E; Sikka SC; Oral DY; Ozakca I; Gur S
Curr Drug Targets; 2018; 19(6):602-612. PubMed ID: 28117002
[TBL] [Abstract][Full Text] [Related]
6. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Ellsworth P
Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
[TBL] [Abstract][Full Text] [Related]
7. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A for the Treatment of Overactive Bladder.
Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
[TBL] [Abstract][Full Text] [Related]
9. Understanding clinic options for overactive bladder.
Bartley JM; Blum ES; Sirls LT; Peters KM
Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
[TBL] [Abstract][Full Text] [Related]
10. Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?
Sacco E; Bientinesi R
Int Urogynecol J; 2015 May; 26(5):629-40. PubMed ID: 25377296
[TBL] [Abstract][Full Text] [Related]
11. Current and future pharmacotherapy for treating overactive bladder.
Thiagamoorthy G; Cardozo L; Robinson D
Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with β3 -adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: Efficacy in rats with bladder overactivity.
Furuta A; Suzuki Y; Kimura S; Koike Y; Egawa S; Yoshimura N
Int J Urol; 2016 May; 23(5):425-30. PubMed ID: 26890938
[TBL] [Abstract][Full Text] [Related]
13. [Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
Boudy AS; Thubert T
Prog Urol; 2015 Jun; 25(8):497-8. PubMed ID: 25748787
[No Abstract] [Full Text] [Related]
14. Mirabegron: A new option in treating overactive bladder.
Turpen HC; Zimmern PE
JAAPA; 2015 Nov; 28(11):16, 18. PubMed ID: 26501573
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Bywater M; Kessler TM
Praxis (Bern 1994); 2017; 106(21):1175-1181. PubMed ID: 29041854
[No Abstract] [Full Text] [Related]
17. Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm.
Osman NI; Aldamanhori R; Mangera A; Chapple CR
Urol Clin North Am; 2016 Aug; 43(3):337-49. PubMed ID: 27476126
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of the overactive bladder.
Andersson KE
Discov Med; 2009 Oct; 8(42):118-24. PubMed ID: 19833057
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
20. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Thiagamoorthy G; Giarenis I; Cardozo L
Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
